| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 06/20/2013 | US20130156770 Binding molecules for bcma and cd3 |
| 06/20/2013 | US20130156769 Binding molecules for bcma and cd3 |
| 06/20/2013 | US20130156767 Method for treating cachexia using antagonist antibodies against gdf-8 |
| 06/20/2013 | US20130156766 Treatment of dry age related macular degeneration |
| 06/20/2013 | US20130156762 Mechanically-Activated Cation Channels |
| 06/20/2013 | US20130156761 Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same |
| 06/20/2013 | US20130156758 Optimized Fc Variants and Methods for Their Generation |
| 06/20/2013 | US20130156754 Optimized Fc Variants and Methods For Their Generation |
| 06/20/2013 | US20130156751 Treatment of diseases |
| 06/20/2013 | US20130156729 Mammalian Receptor Proteins; Related Reagents and Methods |
| 06/20/2013 | US20130156696 Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse |
| 06/20/2013 | US20130156695 Use of zcytor17 ligand antagonists for treating inflammatory diseases |
| 06/20/2013 | US20130156694 Hsp70 fusion protein conjugates and uses thereof |
| 06/20/2013 | US20130156693 Anti-tat226 antibodies and immunoconjugates |
| 06/20/2013 | US20130156691 Antibody Therapy |
| 06/20/2013 | DE102011121238A1 Einzeldomänen-antikörper gegen clostridium difficile toxine Single-domain antibodies against Clostridium difficile toxins |
| 06/20/2013 | DE102011121237A1 Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa Single domain antibodies against Clostridium difficile toxin CDTa |
| 06/20/2013 | CA2858389A1 Soluble igf receptor fc fusion proteins and uses thereof |
| 06/20/2013 | CA2855840A1 Composition and method for the diagnosis and treatment of iron-related disorders |
| 06/20/2013 | CA2855570A1 Composition and method for the diagnosis and treatment of iron-related disorders |
| 06/20/2013 | CA2853889A1 Antibodies against human csf-1r and uses thereof |
| 06/20/2013 | CA2853011A1 Methods of purifying antibodies |
| 06/19/2013 | EP2604628A2 Binding members for interleukin-4 receptor alpha (IL-4R) - 173 |
| 06/19/2013 | EP2604627A1 Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK |
| 06/19/2013 | EP2604626A1 Fragment of humanized anti-egfr antibody substituted-lysine variable fragment and use thereof |
| 06/19/2013 | EP2604625A1 Generation of binding molecules |
| 06/19/2013 | EP2604624A1 Bowman-Birk protease Inhibitor (BBI) binding peptides, and uses thereof in the separation, detection or purification of BBI. |
| 06/19/2013 | EP2604280A2 Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
| 06/19/2013 | EP2604279A1 Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
| 06/19/2013 | EP2604278A1 Anti-KIR antibodies, formulations, and uses thereof |
| 06/19/2013 | EP2604276A1 Use of antibodies against nk1, nk2 and/or nk3 receptors in cancer treatment |
| 06/19/2013 | EP2604111A2 Animal models and therapeutic molecules |
| 06/19/2013 | EP2604110A2 Animal models and therapeutic molecules |
| 06/19/2013 | EP2603530A2 Anti-fap antibodies and methods of use |
| 06/19/2013 | EP2603529A1 Anti-tenascin-c a2 antibodies and methods of use |
| 06/19/2013 | EP2603528A1 Fab-glycosylated antibodies |
| 06/19/2013 | EP2603527A1 Humanized egfr antibodies |
| 06/19/2013 | EP2603526A1 Monomeric polypeptides comprising variant fc regions and methods of use |
| 06/19/2013 | EP2603525A1 Antibodies to il-1beta and il-18, for treatment of disease |
| 06/19/2013 | EP2603524A1 Amyloid-beta binding proteins |
| 06/19/2013 | EP2603523A1 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| 06/19/2013 | EP2603522A1 Improved anti-serum albumin binding variants |
| 06/19/2013 | EP2603521A2 Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
| 06/19/2013 | EP2603520A2 Erythrocyte-binding therapeutics |
| 06/19/2013 | EP2603237A2 Anti-hemagglutinin antibody compositions and methods of use thereof |
| 06/19/2013 | EP2603236A1 Anti-syndecan-4 antibodies |
| 06/19/2013 | CN1798834B Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survivial of transplanted hematopoietic stem cell, human monoclon |
| 06/19/2013 | CN1668335B Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s) |
| 06/19/2013 | CN103168104A Anti-tumor antigen antibodies and methods of use |
| 06/19/2013 | CN103168049A Anti-tenascin-c a2 antibodies and methods of use |
| 06/19/2013 | CN103168048A Dimeric vstm3 fusion proteins and related compositions and methods |
| 06/19/2013 | CN103160515A Preparation method for single-chain antibody based on hybridoma cell |
| 06/19/2013 | CN103160475A Enterovirus 71 type viral strain, its application, vaccine and preparation method |
| 06/19/2013 | CN103160474A Enterovirus 71 type virus strain, vaccine, animal model establishment method |
| 06/19/2013 | CN103160472A Aflatoxin sterigmatocystin hybridoma cell strain, antibody, immunoadsorbent, immunoaffinity column, kit and applications of immunoadsorbent, immunoaffinity column and kit |
| 06/19/2013 | CN103160471A Ochratoxin A hybridoma cell strain, antibody, compound immunoadsorbent, immunoaffinity column, kit and applications of immunoadsorbent, immunoaffinity column and kit |
| 06/19/2013 | CN103160470A Hybridoma cell strain, antibody, immunoadsorbent, immunoaffinity column, kit and applications of immunoadsorbent, immunoaffinity column and kit |
| 06/19/2013 | CN103159855A Fusion protein, use thereof, and anti-malarial vaccine and antibody thereof |
| 06/19/2013 | CN103159853A Completely humanized genetic engineering fragment antigen binding (Fab) antibody against hepatitis C virus core antigen, preparation method thereof and application |
| 06/19/2013 | CN103159852A Method for synthesizing specific artificial antigen of clenbuterol |
| 06/19/2013 | CN103159824A Full sealed pipelined protein purification system and application on preparation of sterile apyrogeneity protein pharmaceutical medicine |
| 06/19/2013 | CN103159778A Hapten, antigen, corresponding antibody and application thereof in detection of artemether |
| 06/19/2013 | CN103159669A Meperidine monoclonal antibodies, immunoassay plates and kits |
| 06/19/2013 | CN103159648A Bensulfuron-methyl universal hapten, artificial antigen, preparation method and application thereof |
| 06/19/2013 | CN103157296A Preparation method of citrinin immunoaffinity column |
| 06/19/2013 | CN102719405B Hybridoma cell strain 1C8 and anti-aflatoxin G1 monoclonal antibody produced by same |
| 06/19/2013 | CN102690789B Hybridoma cell strain secreting tetanus exotoxin monoclonal antibody, monoclonal antibody prepared by same, Fab antibody and application |
| 06/19/2013 | CN102586193B Monoclonal antibody for resisting duck tembusu virus, hybridoma strain and application thereof |
| 06/19/2013 | CN102351947B Ev71早期诊断方法及试剂盒 Ev71 early diagnostic methods and kits |
| 06/19/2013 | CN102257138B Tumor antigen peptide and use thereof |
| 06/19/2013 | CN102250247B Bispecific antibody to VEGF/ANG2 and application thereof |
| 06/19/2013 | CN102202655B Lyophilized formulatons of engineered anti-il-23p19 antibodies |
| 06/19/2013 | CN102127167B Whole human TNF alpha (tumor necrosis factor alpha) monoclonal antibody and preparation and application thereof |
| 06/19/2013 | CN101995463B Composition for detecting rheumatoid arthritis immune antibody by dot immuno-gold filtration assay |
| 06/19/2013 | CN101915835B Lily mottle virus double-antibody sandwich enzyme-linked immunosorbent assay kit and preparation method |
| 06/19/2013 | CN101874041B Modified antibody constant region |
| 06/19/2013 | CN101863977B J substock lymphoid leuoosis-resistant polyclonal antibody and preparation method thereof |
| 06/19/2013 | CN101747435B Monoclonal antibody (hybrid tumor) for neutralizing CYR61 and applications thereof |
| 06/19/2013 | CN101687923B ED-A antigen of fibrinogen associated with the neovasculature of tumour metastases |
| 06/19/2013 | CN101687920B Heavy chain mutant leading to improved immunoglobulin production |
| 06/19/2013 | CN101679525B Predictive renal safety biomarkers and biomarker signatures to monitor kidney function |
| 06/19/2013 | CN101602793B Immunoregulatory polypeptide for preventing and/or treating rheumatoid arthritis and application thereof |
| 06/19/2013 | CN101580538B WT1-origin HLA-DR-binding antigen peptide |
| 06/19/2013 | CN101460519B Human binding molecules having killing activity against staphylococci and uses thereof |
| 06/19/2013 | CN101426528B Methods of using antibodies against human il-22 |
| 06/19/2013 | CN101370831B Methods and compositions for treating allergic diseases |
| 06/19/2013 | CN101316930B T-cell adhesion molecule and antibody directed against the molecule |
| 06/19/2013 | CN101233155B 人抗表皮生长因子受体抗体 Human anti-epidermal growth factor receptor antibody |
| 06/19/2013 | CN101180317B Method for the purification of antibodies |
| 06/18/2013 | US8466263 Carbonic anhydrase IX (G250) anitbodies |
| 06/18/2013 | US8466262 Variable region sequences of IL-31 monoclonal antibodies and methods of use |
| 06/18/2013 | US8466261 Therapeutic using a bispecific antibody |
| 06/18/2013 | US8466091 Focused libraries of genetic packages |
| 06/18/2013 | US8465756 Immunogenic peptides of tumor associated antigen L6 and uses thereof in cancer therapy |
| 06/18/2013 | US8465750 Staphylococcus aureus proteins and nucleic acids |
| 06/18/2013 | US8465746 Compositions and methods for treatment, research and therapeutic applications for malaria |
| 06/18/2013 | US8465744 Method of treating inflammation by administering human IL-1B antibodies |
| 06/18/2013 | US8465743 Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| 06/18/2013 | US8465741 Antibodies and methods for making and using them |
| 06/18/2013 | US8465739 Stable aqueous pharmaceutical formulations of daclizumab antibodies |